Fulcrum therapeutics to participate at the oppenheimer 34th annual healthcare life sciences conference

Cambridge, mass., feb. 06, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (the “company”) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the oppenheimer 34th annual healthcare life sciences conference, being held virtually on tuesday, february 13, 2024 at 1:20 p.m. et. management will also participate in one-on-one investor meetings.
FULC Ratings Summary
FULC Quant Ranking